Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) for Coronavirus (DAMPENCOVID Trial)

Phase 2

Recruiting

Research Sponsored by Jon Simmons

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 28 days

Awards & highlights

All Individual Drugs Already Approved

Summary

This trial will test if inhaling a medication called Dornase Alpha can help COVID-19 patients with severe lung problems breathe better and reduce their risk of dying.

Eligible Conditions

Coronavirus

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Mortality at 28 days

Systemic Therapeutic Response

Secondary study objectives

Legnth of Hospital Stay

Legnth of ICU Stay

Pulmonary Function

+1 more

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Treatment ArmExperimental Treatment1 Intervention

Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.

Group II: Placebo Arm 0.9% sodium chloridePlacebo Group1 Intervention

Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.

Do I qualify?Apply below to find out